Last reviewed · How we verify
integrilin — Competitive Intelligence Brief
phase 1
Integrin alpha-IIb/beta-3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
integrilin (integrilin) — University of Cincinnati.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| integrilin TARGET | integrilin | University of Cincinnati | phase 1 | Integrin alpha-IIb/beta-3 | ||
| Aggrastat | TIROFIBAN | Medicure | marketed | Platelet Aggregation Inhibitor | Integrin alpha-IIb/beta-3 | 1998-01-01 |
| Integrilin | EPTIFIBATIDE | Merck & Co. | marketed | Platelet Aggregation Inhibitor [EPC] | Integrin alpha-IIb/beta-3 | 1998-01-01 |
| Reopro | ABCIXIMAB | Johnson & Johnson | marketed | Integrin alpha-IIb/beta-3 | 1993-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- integrilin CI watch — RSS
- integrilin CI watch — Atom
- integrilin CI watch — JSON
- integrilin alone — RSS
Cite this brief
Drug Landscape (2026). integrilin — Competitive Intelligence Brief. https://druglandscape.com/ci/integrilin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing